Up-front costs and the time it takes to get through clinical trials and approval are key discouraging factors, as is opportunity cost. It is much more profitable for a big pharmaceutical concern to devote its financial and development resources to a drug that people are going to take every day than to one that is used only rarely and that will be rationed in order to preserve its effectiveness.
